Pendulum Swings Again: Entresto Patent In India Restored, For Now

Patent pertaining to Novartis’s Entresto re-instated for now in India after a two-judge bench stays a previous order that set aside the grant of the patent. Will that put Indian firms that launched generic versions of the heart failure therapy at risk of infringement in the interim?

Twists And Turns In Entresto Patent Battle In India • Source: Shutterstock

Twists and turns around the patent battle pertaining to Novartis’s blockbuster heart-failure therapy Entresto (sacubitril/valsartan) continue to play out in India, this time the pendulum swinging the way of the Swiss multinational.

Days after the Delhi High Court set aside the 14 December 2022 decision by an assistant controller of patents and...